Recently, we have shown that using PDGFβR-specific delivery of IFNγ to activated HSC; acute and advanced liver fibrosis in vivo could be significantly inhibited with minimal adverse effects [20], [23]. Here, IFNG is linked to Hepatic fibrosis.